NEWS

Ovarian Cancer | Page 5 - Cancer Network

www.cancernetwork.com - 12/15/11

Ovarian Cancer Staging

emedicine.medscape.com - 10/26/11

Small Study Shows Promise of a Vaccine for Metastatic Breast and Ovarian Cancer - Cancer Network

www.cancernetwork.com - 11/10/11

PRACTICE GUIDELINES

Guide to Clinical Preventive Services, 2010-2011: Section 2

www.ahrq.gov -

National Guideline Clearinghouse | Hereditary breast and ovarian cancer syndrome.

www.guidelines.gov -

National Guideline Clearinghouse | PET imaging in ovarian cancer: recommendations.

www.guidelines.gov -

JOB LISTINGS

Post a job

FOR PATIENTS

Breast cancer - References - Genetics Home Reference

ghr.nlm.nih.gov - 1/9/12

CTNNB1 - catenin (cadherin-associated protein), beta 1, 88kDa - Genetics Home Reference

ghr.nlm.nih.gov - 1/9/12

Reproductive system - Genetics Home Reference

ghr.nlm.nih.gov - 1/9/12

Order Your Copy!
(2010, 13th Edition)

Please allow 3 – 4 weeks to ship

CONNECT WITH US

	Become a fan on Facebook
	Add us on Google Plus
	Follow us on Twitter
	Sign up for our Newsletters
	Subscribe to our RSS Feed

Ovarian Cancer

FEATURED ARTICLE

Ovarian Cancer: Is it Time for Personalized Approaches?

Ovarian cancer kills roughly 16,000 women each year. While the

disease has traditionally been treated with surgery and chemotherapy,

new targeted therapies show promise.

This week our authors discuss and debate the new treatment

approaches, including the merits of personalized medicine.

MORE FEATURES

February 9, 2012

The Maze of PARP Inhibitors in Ovarian Cancer

The development of poly(ADP-ribose) polymerase (PARP) inhibitors as a new class of anticancer agents has created a tremendous amount of hope in the ovarian cancer community, especially in the high-risk, difficult-to-screen, hereditary ovarian cancer population. More »

February 9, 2012

PARP Inhibition in Epithelial Ovarian Cancer: High Hopes Undergo a Reality Check

This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development. More »

February 9, 2012

The Circuitous Path of PARP Inhibitor Development in Epithelial Ovarian Cancer

Ovarian cancers account for more than 50% of gynecologic cancer deaths. This is attributable to the late stage of the disease at diagnosis. More »

January 19, 2012

A Step Forward Toward Better Characterization of Ovarian Cancer

A new study has made a step forward toward better characterization of sporadic ovarian tumors by identifying their DNA repair protein expression profile. More »

December 15, 2011

Ovarian Cancer

Despite the fact that it is highly curable if diagnosed early, ovarian cancer causes more mortality in American women each year than all other gynecologic malignancies combined. More »

Showing 1 - 5 of 171 results.

Page of 35

First Previous Next Last

CLINICAL TRIALS

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA-51) as Consolidation Following Optimal Debulking and Systemic Chemotherapy for Women With Advanced Stage Ovarian, Tubal or Peritoneal Cancer - Full Text View - ClinicalTrial

www.clinicaltrials.gov -

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

OVATURE (OVArian TUmor REsponse) Study: A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin - Full Text View - ClinicalTrials.gov

www.clinicaltrials.gov -

MEDLINE

Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype.

pubmed.gov - 11/28/11

Although it is well known that ovarian endometriosis occasionally gives rise to ovarian cancers with specific histology such as endometrioid and clear cell carcinomas, its etiology is not fully understood. We have shown that a stressful microenvironment within the endometriotic cyst may lead to cancer development by inducing unique gene expressions, which potentially serves as a molecular marker for treatment modality. In this review, by referring to other articles in this field, we explore how the carcinogenic microenvironment affects the phenotype and gene expression of a cancer, and how we can develop new treatment based on this concept.

Ovarian cancer screening and mortality.

pubmed.gov - 10/12/11

Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.

pubmed.gov - 11/1/11

Variably-spliced prolactin receptors (PRLRs) and PRL are expressed by the ovarian cancer cell lines, TOV-112D, OV-90 and TOV-21G. Incubation in the PRLR antagonists, G129R- or S179D-PRL, or anti-PRL reduced cell number, indicating a functional autocrine PRL growth loop. Added PRL promoted, and the antagonists decreased, cell migration. When cells were stressed, added PRL decreased apoptosis and increased survival, and the antagonists had the opposite effect. Cells expressing higher long:short PRLR ratios had increased growth, survival and migration in response to PRL. Results suggest that PRLR antagonists may be therapeutically beneficial in ovarian cancer.

Trabectedin and ovarian cancer (continued).

pubmed.gov - 10/1/11

Early detection of ovarian cancer: if only we had a "Pap smear" for this disease.

pubmed.gov - 10/1/11

TOPIC INDEX